Zynerba Pharmaceuticals receives FDA approval for cannabinoid therapies
Big medical bet: Why this Philly area pharma company's shares jumped 65 percent in a week
Zynerba Synthetic CBD Gel for Epilepsy Proves Safe but Not Effective in FDA Phase 2 Trial – New Cannabis Ventures
Zynerba Stock is a Medical Cannabis Investment You Can Feel Good About
Zygel - Zynerba
Zynerba Pharmaceuticals Presents During NFXF's 2022 Industry Updates | NFXF
Zynerba Pharmaceuticals Inc updates on its meeting with the US Food and Drug Administration regarding its Fragile X syndrome program using Zygel
Shares of Devon-Based Zynerba Pharmaceuticals Surge After Firm Wins Patent
Zygel's anticipated impact on underserved fragile X syndrome market
SCYNEXIS Inc names Zynerba Pharmaceuticals Inc CEO Armando Anido to its board
Zynerba Pharmaceuticals - Whether They've Cracked The Code For Fully Methylated FX Syndrome Patients (NASDAQ:ZYNE) | Seeking Alpha
Reassessing Zynerba Pharmaceuticals (NASDAQ:ZYNE) | Seeking Alpha
Zynerba hopes to crack fragile X at last | Evaluate
Zynerba Pharma Receives FDA Guidance For Phase 3 Trial Of Zygel; Street Sees 75% Upside
Should You Buy Zynerba Pharmaceuticals Inc (ZYNE) Stock on Thursday?
Zynerba Pharma Receives FDA Guidance For Phase 3 Trial Of Zygel; Street Sees 75% Upside
